These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 915279)
1. Human eosinophil adherence to serum-treated sepharose: granule-associated enzyme release and requirement for activation of the alternative complement pathway. Metcalfe DD; Gadek JE; Raphael GD; Frank MM; Kaplan AP; Kaliner M J Immunol; 1977 Nov; 119(5):1744-50. PubMed ID: 915279 [No Abstract] [Full Text] [Related]
2. Influence of divalent cations upon complement-mediated enzyme release from human polymorphonuclear leukocytes. Goldstein IM; Hoffstein ST; Weissmann G J Immunol; 1975 Sep; 115(3):665-70. PubMed ID: 1151072 [TBL] [Abstract][Full Text] [Related]
3. Complement-mediated leukocyte adherence to infective larvae of Dipetalonema viteae (Filarioidea): requirement for eosinophils or eosinophil products in effecting macrophage adherence. Haque A; Ouaissi A; Santoro F; des Moutis I; Capron A J Immunol; 1982 Nov; 129(5):2219-25. PubMed ID: 6889619 [TBL] [Abstract][Full Text] [Related]
4. Adherence of human eosinophils to infective filariform larvae of Necator americanus in vitro. Desakorn V; Suntharasamai P; Pukrittayakamee S; Migasena S; Bunnag D Southeast Asian J Trop Med Public Health; 1987 Mar; 18(1):66-72. PubMed ID: 3660070 [TBL] [Abstract][Full Text] [Related]
5. The role of complement in innate, adaptive and eosinophil-dependent immunity to the nematode Nippostrongylus brasiliensis. Giacomin PR; Gordon DL; Botto M; Daha MR; Sanderson SD; Taylor SM; Dent LA Mol Immunol; 2008 Jan; 45(2):446-55. PubMed ID: 17675237 [TBL] [Abstract][Full Text] [Related]
6. [The mechanism of arylsulfatase release from rat eosinophils]. Torii T; Sueishi M; Kanai H; Tomioka H; Kumagai A Arerugi; 1983 Jan; 32(1):14-21. PubMed ID: 6305313 [No Abstract] [Full Text] [Related]
7. Activation of the alternative complement pathway in normal human serum by Loa loa and Brugia malayi infective stage larvae. Yates JA; Higashi GI; Lowichik A; Orihel TC; Lowrie RC; Eberhard ML Acta Trop; 1985 Jun; 42(2):157-63. PubMed ID: 2862778 [TBL] [Abstract][Full Text] [Related]
8. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. Schlesinger LS; Bellinger-Kawahara CG; Payne NR; Horwitz MA J Immunol; 1990 Apr; 144(7):2771-80. PubMed ID: 2108212 [TBL] [Abstract][Full Text] [Related]
9. The human alternative complement pathway: biology and immunopathology of activation and regulation. Kazatchkine MD; Nydegger UE Prog Allergy; 1982; 30():193-234. PubMed ID: 7041132 [No Abstract] [Full Text] [Related]
10. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions. Robertson J; Caldwell JR; Castle JR; Waldman RH J Immunol; 1976 Sep; 117(3):900-3. PubMed ID: 956659 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein. Winqvist I; Olofsson T; Olsson I Immunology; 1984 Jan; 51(1):1-8. PubMed ID: 6317543 [TBL] [Abstract][Full Text] [Related]
12. In vitro study of complement dependent active adherence on SLE and RA leukocytes. Dénes L; Falus A; Böhm U; Merétey K Acta Physiol Acad Sci Hung; 1981; 58(1):21-9. PubMed ID: 7342695 [TBL] [Abstract][Full Text] [Related]
13. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. Verbrugh HA; Peterson PK; Nguyen BY; Sisson SP; Kim Y J Immunol; 1982 Oct; 129(4):1681-7. PubMed ID: 7108223 [TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Zaragoza O; Casadevall A Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038 [TBL] [Abstract][Full Text] [Related]
15. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. Mold C; Nemerow GR; Bradt BM; Cooper NR J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273 [TBL] [Abstract][Full Text] [Related]
16. Activation of human complement by liposomes: serum factor requirement for alternative pathway activation. Mold C; Gewurz H J Immunol; 1980 Aug; 125(2):696-700. PubMed ID: 7391575 [No Abstract] [Full Text] [Related]
17. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia. Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203 [TBL] [Abstract][Full Text] [Related]
18. Mouse factor B of the alternative pathway of complement activation. I. Purification, characterization, and functional behavior. Bitter-Suermann D; Burger R; Brade V; Hadding U J Immunol; 1976 Nov; 117(5 Pt.2):1799-804. PubMed ID: 993580 [TBL] [Abstract][Full Text] [Related]
19. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296 [TBL] [Abstract][Full Text] [Related]
20. Effects of activated complement components on enzyme secretion by macrophages. Schorlemmer HU; Allison AC Immunology; 1976 Nov; 31(5):781-8. PubMed ID: 992710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]